The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to pause dosing in another study.
Capricor has licenced out the US, European and Japanese marketing rights to the therapy to Nippon. Image credit: Pavel Kapysh / Shutterstock. Capricor Therapeutics has released more positive ...
Duchenne muscular dystrophy (DMD) is a neuromuscular disease causing progressive skeletal muscle weakness and fatigue. The research team led by Associate Professor Hidetoshi Sakurai (Department of ...